Trial Profile

A Multicenter, Double-Masked, Phase 1b Study Evaluating the Safety, Tolerability, and Dose-Response of Topical AG-80308 in Patients With Dry Eye Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Jun 2023 According to Allgenesis Biotherapeutics Media Release, company stated moving this program into Phase 2, where we will evaluate 2 doses of AG-80308 in formulation B against vehicle. It has begun preparations to support initiation of the Phase 2 trial in 1Q2024
19 Jun 2023 According to Allgenesis Biotherapeutics Media Release, company has announced topline topline data from this study for AG-80308, a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of Dry Eye Disease (DED).
19 Jun 2023 Results presented in an Allgenesis Biotherapeutics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com